Seres Therapeutics IncNASDAQ:MCRBNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.9046
- TODAY'S CHANGE (%)0.0926 (11.3978%)
- Bid / Lots0.9016/ 1
- Ask / Lots0.9075/ 10
- Open / Previous Close0.8245 / 0.8120
- Day Range
- 52 Week Range
- Volume5,519,851
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MCRB |
|---|---|---|
| 09:32 ET | 328552 | 0.82505 |
| 09:34 ET | 47860 | 0.828 |
| 09:36 ET | 10833 | 0.8279 |
| 09:38 ET | 31152 | 0.828 |
| 09:39 ET | 25988 | 0.8276 |
| 09:41 ET | 21418 | 0.828 |
| 09:43 ET | 41397 | 0.851 |
| 09:45 ET | 126209 | 0.86355 |
| 09:48 ET | 161887 | 0.86399 |
| 09:50 ET | 71858 | 0.8638 |
| 09:52 ET | 110435 | 0.8601 |
| 09:54 ET | 150499 | 0.8638 |
| 09:56 ET | 135266 | 0.869299 |
| 09:57 ET | 141860 | 0.8602 |
| 09:59 ET | 64542 | 0.87375 |
| 10:01 ET | 164700 | 0.8701 |
| 10:03 ET | 18579 | 0.8735 |
| 10:06 ET | 107577 | 0.8894 |
| 10:08 ET | 104723 | 0.887499 |
| 10:10 ET | 80205 | 0.8911 |
| 10:12 ET | 68984 | 0.8903 |
| 10:14 ET | 21601 | 0.8917 |
| 10:15 ET | 88612 | 0.8836 |
| 10:17 ET | 22089 | 0.890555 |
| 10:19 ET | 66490 | 0.89115 |
| 10:21 ET | 112408 | 0.89 |
| 10:24 ET | 160452 | 0.898 |
| 10:26 ET | 210964 | 0.89799 |
| 10:28 ET | 129276 | 0.8911 |
| 10:30 ET | 58631 | 0.8973 |
| 10:32 ET | 45247 | 0.8933 |
| 10:33 ET | 63231 | 0.8979 |
| 10:35 ET | 85835 | 0.9049 |
| 10:37 ET | 19827 | 0.903 |
| 10:39 ET | 42931 | 0.907 |
| 10:42 ET | 31442 | 0.906801 |
| 10:44 ET | 53293 | 0.907 |
| 10:46 ET | 19794 | 0.907 |
| 10:48 ET | 14431 | 0.907 |
| 10:50 ET | 28781 | 0.907 |
| 10:51 ET | 20175 | 0.907 |
| 10:53 ET | 17087 | 0.907 |
| 10:55 ET | 108675 | 0.9114 |
| 10:57 ET | 113887 | 0.9198 |
| 11:00 ET | 95701 | 0.91235 |
| 11:02 ET | 41185 | 0.9043 |
| 11:04 ET | 40604 | 0.9253 |
| 11:06 ET | 60678 | 0.92035 |
| 11:08 ET | 66252 | 0.919799 |
| 11:09 ET | 19226 | 0.91535 |
| 11:11 ET | 34850 | 0.9199 |
| 11:13 ET | 87890 | 0.9256 |
| 11:15 ET | 204050 | 0.9026 |
| 11:18 ET | 150896 | 0.9011 |
| 11:20 ET | 36710 | 0.9099 |
| 11:22 ET | 18795 | 0.92 |
| 11:24 ET | 33803 | 0.916 |
| 11:26 ET | 57518 | 0.916 |
| 11:27 ET | 10965 | 0.916 |
| 11:29 ET | 12910 | 0.9139 |
| 11:31 ET | 8439 | 0.916 |
| 11:33 ET | 91372 | 0.90645 |
| 11:36 ET | 17715 | 0.90715 |
| 11:38 ET | 66503 | 0.8992 |
| 11:40 ET | 12554 | 0.907 |
| 11:42 ET | 21358 | 0.907 |
| 11:44 ET | 33037 | 0.907 |
| 11:45 ET | 57674 | 0.9089 |
| 11:47 ET | 36139 | 0.92435 |
| 11:49 ET | 87751 | 0.9368 |
| 11:51 ET | 76273 | 0.9092 |
| 11:54 ET | 59020 | 0.8982 |
| 11:56 ET | 3200 | 0.9013 |
| 11:58 ET | 59376 | 0.90735 |
| 12:00 ET | 51563 | 0.90385 |
| 12:02 ET | 6630 | 0.9034 |
| 12:03 ET | 34438 | 0.90265 |
| 12:05 ET | 86135 | 0.9081 |
| 12:07 ET | 56415 | 0.90455 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Seres Therapeutics Inc | 123.0M | -1.5x | --- |
Rigel Pharmaceuticals Inc | 136.6M | -7.2x | --- |
Karyopharm Therapeutics Inc | 96.4M | -0.6x | --- |
Acorda Therapeutics Inc | 186.3K | 0.0x | --- |
CytomX Therapeutics Inc | 100.5M | 6.6x | --- |
FibroGen Inc | 71.8M | -0.3x | --- |
Company Information
Seres Therapeutics, Inc. is a commercial-stage microbiome therapeutics company. It is focused on the development and commercialization of a novel class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead program, VOWST, is to prevent recurrence of Clostridioides difficile infection (CDI) in patients 18 or older following antibacterial treatment for recurrent CDI. Building upon VOWST, it is developing novel microbiome therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, an oral microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to prevent enteric-derived infections and resulting blood stream infections and induce immune tolerance responses to reduce the incidence of GvHD in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Contact Information
- Headquarters
- 101 Cambridge Park DriveCAMBRIDGE, MA, United States 02140
- Phone
- 617-945-9626
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Stephen Berenson
- President, Chief Executive Officer, Director
- Eric Shaff
- Chief Financial Officer, Executive Vice President
- Marella Thorell
- Executive Vice President, Chief Technology Officer
- David Ege
- Executive Vice President, Chief Scientific Officer
- Matthew Henn
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $123.0M |
|---|---|
Revenue (TTM) | $126.8M |
Shares Outstanding | 151.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.96 |
EPS | $-0.61 |
Book Value | $-0.33 |
P/E Ratio | -1.5x |
Price/Sales (TTM) | 1.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -61.98% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
